Novo taps e-therapeutics for diabetes target discovery drive

Novo Nordisk has enlisted e-therapeutics to support target discovery efforts at its recently opened research center in Oxford, U.K. The collaboration will see e-therapeutics apply its platform for finding synergistic target combinations to a “specific area” of Type 2 diabetes.